Trade

Divi's Laboratories share price

Moderate risk
  • 23%Low risk
  • 23%Moderate risk
  • 23%Balanced risk
  • 23%High risk
  • 23%Extreme risk
  • ₹6,230.60(-1.06%)
    April 17, 2026 15:29:45 PM IST
    • NSE
    • BSE
  • Vol : 172.50 K (NSE + BSE)
    Last 20 day avg : 318.22 K

Divi's Laboratories is trading -1.06% lower at Rs 6,230.60 as compared to its last closing price. Divi's Laboratories has been trading in the price range of 6,324.65 & 6,214.00. Divi's Laboratories has given -1.55% in this year & 7.00% in the last 5 days. There are 28 analysts who have initiated coverage on Divi's Laboratories. There are 7 analysts who have given it a strong buy rating & 7 analysts have given it a buy rating. 7 analysts have given the stock a sell rating.The company posted a net profit of 583.00 Crores in its last quarter.Listed peers of Divi's Laboratories include Dr Reddy's Laboratories (1.45%), Torrent Pharmaceuticals (0.78%), Cipla (0.61%).The Mutual Fund holding in Divi's Laboratories was at 13.42% in 31 Mar 2026. The MF holding has decreased from the last quarter. The FII holding in Divi's Laboratories was at 20.29% in 31 Mar 2026. The FII holding has increased from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Explore on
Loading...
Key Metrics

Updated on Apr 18, 2026, 05:28 PM UTC

  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    0.72
    Low volatility
  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.48
    Lower than industry
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    11.16
    Higher than historical values
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    67.35
    Higher than historical values
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    -7.06
    Indicates undervaluation
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    -
Price range
Day Range
Lowest
6,214.00
Highest
6,324.65
52 week range
Lowest
5,592.70
Highest
7,077.70
Divi's Laboratories Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Dr Reddy's Laboratories
Moderately Bearish
1,239.001.451,03,409.1618.633.140.632.34
Torrent Pharmaceuticals
Bullish
4,188.950.781,41,773.1067.3217.10.8317.62
Cipla
Moderately Bearish
1,238.300.611,00,027.7322.953.870.870.81
Sun Pharmaceutical Industries
Bearish
1,675.20-1.064,01,936.5936.245.770.920.50
Lupin
Bullish
2,321.40-0.221,06,303.1928.785.590.5711.80
Mutual Fund Ownership
View all
Quant Healthcare Fund Regular Growth
NA
  • Amount Invested (Cr.) 41.25
  • % of AUM 9.89
Nippon India Pharma Fund - Growth
NA
  • Amount Invested (Cr.) 792.66
  • % of AUM 9.49
ITI Pharma and Healthcare Fund Regular Growth
NA
  • Amount Invested (Cr.) 20.16
  • % of AUM 9.12
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Growth
NA
  • Amount Invested (Cr.) 497.54
  • % of AUM 9.03
PGIM India Healthcare Fund Regular Growth
NA
  • Amount Invested (Cr.) 9.36
  • % of AUM 8.60
Divi's Laboratories Corporate Actions
View all
  • Board Meetings
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
Meeting DatePurpose
2026-02-11Quarterly Results
2025-11-07Quarterly Results
2025-08-06Quarterly Results
2025-05-17Audited Results & Dividend
2025-02-03Quarterly Results
About the company Divi's Laboratories
  • IndustryBiotechnology & Drugs
  • ISININE361B01024
  • BSE Code532488
  • NSE CodeDIVISLAB
Divi's Laboratories Limited is an India-based company, which is engaged in pharmaceutical ingredients (APIs), intermediates and nutraceutical ingredients with predominance in exports. The Company’s products include Bupropion HCl, Capecitabine, Carbidopa, Diltiazem HCl, Dextromethorphan Base, Dextromethorphan HBr, Gabapentin, Iopamidol, Iohexol, Irbesartan, Lacosamide, Levetiracetam, Levodopa, Losartan, Nabumetone, Naproxen, Naproxen Sodium, Olmesartan Medoxomil, Pregabalin, Ticagrelor, Triprolidine HCl, Valacyclovir HCl, Valsartan, Venlafaxine HCl, Vigabatrin, and others. The Company is also engaged in custom synthesis (contract manufacturing services) of APIs and Intermediates for global innovator companies with a portfolio of products across diverse therapeutic areas. The Company’s subsidiaries include Divis Laboratories (USA) Inc. and Divi’s Laboratories Europe AG.
  • Management Info
  • Kiran DiviChief Executive Officer, Whole-Time Director
  • Venkatesa PasumarthyChief Financial Officer
  • Manoranjan JastiChief Information Officer
  • Meka Satish ChoudhuryCompliance Officer, Company Secretary
  • Murali DiviManaging Director, Executive Director
  • Nilima DiviWhole-Time Director - (Commercial)
  • Nimmagadda RamanaExecutive Director
  • Sureddy RaoWhole-Time Director - (Manufacturing)
Divi's Laboratories Share Price FAQs

Divi's Laboratories is trading at 6230.60 as on Fri Apr 17 2026 09:59:45. This is -1.06% lower as compared to its previous closing price of 6297.50.

The market capitalization of Divi's Laboratories is 165402.85 Cr as on Fri Apr 17 2026 09:59:45.

The average broker rating on Divi's Laboratories is Hold. The breakup of analyst rating is given below -

  • 7 analysts have given a strong buy rating
  • 7 analysts have given a buy rating
  • 5 analysts have given a hold rating
  • 7 analysts have given a sell rating
  • 2 analysts have given a strong sell rating

The 52 wk high for Divi's Laboratories is 7077.70 whereas the 52 wk low is 5592.70

Divi's Laboratories can be analyzed on the following key metrics -

  • TTM P/E: 68.41
  • Sector P/E: -
  • Dividend Yield: 0.48%
  • D/E ratio: -

Divi's Laboratories reported a net profit of 2191.00 Cr in 2025.

The Mutual Fund Shareholding was 13.42% at the end of 31 Mar 2026.

Quick Links
EQUITY QUICK LINKS
Divi's Laboratories QUICK LINKS
FROM MARKETS
RELATED LINKS
Quarterly Results
Home/Market/Market Stats/  Divi's Laboratories share price
✕

Wait for it…

Log in to our website to save your bookmarks. It'll just take a moment.

✕

Wait for it…

Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.